

applicable to human IBD [J. Clin. Invest. (2005) 115, 3057–3071].

Available for licensing are methods for treating or preventing the inflammatory response of IBDs by intrarectally or intraperitoneally administering a therapeutic effective amount of NF- $\kappa$ B decoy ODN. Claims are directed to treatment of Th1 and Th2 inflammatory response and these studies suggest that NF- $\kappa$ B decoy ODNs targeting the consensus NF- $\kappa$ B binding site and encapsulated in a viral envelope represent an effective approach for the treatment of IBDs.

Related IBD technologies available for licensing also include IL-13 modulators and inhibitors (HHS Reference No. E-131-2002/0-PCT-02, WO 2004/001655, filed 14 June 2002) and IL-13 mutant and chimeric molecules (HHS Reference No. E-003-2005/0-US-01, U.S. Provisional Patent Application No. 60/671,624 filed 15 April 2005).

In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.

#### **Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules**

Warren Strober (NIAID), Ivan Fuss (NIAID), Peter Mannon (NIAID), Jan Preiss (NIAID), Raj Puri (FDA), Koji Kawakami (FDA), Stefan Fichtner-Feigl (NIAID), and Atsushi Kitani (NIAID)

U.S. Provisional Patent Application No. 60/671,624 filed 15 April 2005 (HHS Reference No. E-003-2005/0-US-01); PCT International Application filed 14 April 2006 (HHS Reference No. E-003-2005/0-PCT-02)

Licensing Contact: Susan Carson, D. Phil; 301/435-5020; [carsonsu@mail.nih.gov](mailto:carsonsu@mail.nih.gov).

Ulcerative colitis (UC) is a chronic inflammatory disease of the colorectum and affects approximately 400,000 people in the United States. The cause of UC is not known, although an abnormal immunological response to bacterial antigens in the gut microflora is thought to be involved. Present treatments for UC include anti-inflammatory therapy using aminosalicylates or corticosteroids, as well as immunomodulators and diet. However, 25–40% of ulcerative colitis patients must eventually have their colons removed due to massive bleeding, severe illness, rupture of the colon, risk of cancer or due to side effects of corticosteroids and novel treatments are still actively being sought. NIH scientists and their

collaborators have used a mouse model of experimental colitis (oxazolone colitis, OC) to show that IL-13, a Th2 cytokine, is a significant pathologic factor in OC and that neutralizing IL-13 in these animals effectively prevents colitis [Immunity (2002) 17, 629–638].

OC is a colitis induced by intrarectal administration of a relatively low dose of the haptening agent oxazolone subsequent to skin sensitization with oxazolone. A highly reproducible and chronic colonic inflammation is obtained that is histologically similar to human ulcerative colitis. Studies show that Natural Killer T (NKT) cells, rather than conventional CD4+T cells, mediate oxazolone colitis and are the source of IL-13 as well as being activated by CD1-expressing intestinal epithelial cells. Tissue removed from ulcerative colitis patients were also shown to contain increased numbers of nonclassical NKT cells that produce markedly increased amounts of IL-13 and that in keeping with epithelial damage being a key factor in UC, these NKT cells are cytotoxic for epithelial cells [J. Clin. Invest. (2004) 113, 1490–1497]. Building on their previous work, scientists at NIAID and FDA have shown that an IL-13 chimeric fusion protein linked to an effector molecule was able to prevent colitis in a mouse model of ulcerative colitis.

Available for licensing are methods for treating or preventing the inflammatory response of IBD by inhibiting the binding of IL-13 to IL-13 receptors on NKT cells. Additionally, these mutant and chimeric IL-13 molecules are able to block the chronic inflammatory response that results in fibrosis as seen in Crohn's disease. Preventing the inflammatory response of colitis by either modulating or blocking IL-13 and NKT cell activity continues to be an effective therapeutic approach in animal models of colitis with implications for the treatment of human ulcerative colitis and for the treatment of fibrosis associated with Crohn's disease.

Related IBD technologies available for licensing also include IL-13 modulators and inhibitors (HHS Reference No. E-131-2002/0-PCT-02, WO 2004/001655, filed 14 June 2002) and NF- $\kappa$ B decoy oligonucleotides [HHS Reference No. E-108-2005/0-US-01, U.S. Patent Application No. 11/125,919, filed 10 May 2005; J. Clin. Invest. (2005) 115, 3057–3071].

In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.

Dated: June 21, 2006.

**David R. Sadowski,**

*Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 06-5868 Filed 6-27-06; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Center for Research Resources; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Research Resources Special Emphasis Panel, CTSA Center Grants #1.

*Date:* July 11–12, 2006.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Sheryl K. Brining, PhD, Scientific Review Administrator, Director, Office of Review, NCCR, National Institutes of Health, 6701 Democracy Boulevard, 1 Democracy Plaza, Room 1074, MSC 4874, Bethesda, MD 20892-4874. (301) 435-0811. [sb44k@nih.gov](mailto:sb44k@nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* National Center for Research Resources Special Emphasis Panel, CTSA Center Grants #2.

*Date:* July 20–21, 2006.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Guo Zhang, PhD, Scientific Review Administrator, National Center for Research Resources/OR, National Institutes of Health, 6701 Democracy Boulevard, 1 Democracy Plaza, Room 1064, Bethesda, MD 20892-4874. (301) 435-0812. [zhanggu@nih.gov](mailto:zhanggu@nih.gov).

*Name of Committee:* National Center for Research Resources Special Emphasis Panel, Planning Grants for CTSA.

*Date:* July 25–26, 2006.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Mohan Viswanathan, PhD, Deputy Director, Office of Review, NCRR, National Institutes of Health, 6701 Democracy Boulevard, Room 1084, MSC 4874, 1 Democracy Plaza, Bethesda, MD 20892–4874. (301) 435–0829. [mv10f@nih.gov](mailto:mv10f@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.371, Biomedical Technology; 93.389, Research Infrastructure, 93.306, 93.333, National Institutes of Health, HHS)

Dated: June 20, 2006.

**Linda Payne,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06–5718 Filed 6–27–06; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Eye Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Eye Institute Special Emphasis Panel; Training in Neuroimaging: Integrating First Principles and Applications.

*Date:* July 10, 2006.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

*Contact Person:* Houman H. Araj, PhD, Scientific Review Administrator, Division of Extramural Research, National Eye Institute, NIH, 5635 Fishers Lane, Suite 1300, Bethesda, MD 20892–9602. 301–451–2020. [haraj@mail.nih.gov](mailto:haraj@mail.nih.gov).

*Name of Committee:* National Eye Institute Special Emphasis Panel; NEI Clinical applications.

*Date:* July 28, 2006.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.

*Contact Person:* Anne E. Schaffner, PhD, Scientific Review Administrator, Division of Extramural Research, National Eye Institute, 5635 Fishers Lane, Suite 1300, MSC 9300, Bethesda, MD 20892–9300. (301) 451–2020. [aes@nei.nih.gov](mailto:aes@nei.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: June 20, 2006.

**Linda Payne,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06–5722 Filed 6–27–06; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Microbiology, Infectious Diseases and AIDS Initial Review Group; Acquired Immunodeficiency Syndrome Research Review Committee AIDS Research Review Committee (AIDSRRRC).

*Date:* July 12–13, 2006.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Courtyard Gaithersburg Washington Center, 204 Boardwalk Place, Gaithersburg, MD 20878.

*Contact Person:* Peter R. Jackson, PhD, Chief, ACERB, Scientific Review Program, Division of Extramural Activities/NIH/ NIAID/DHHS, 6700 B Rockledge Drive, MSC 7616, Room 3133, Bethesda, MD 20892–7616. 301–496–2550. [pjackson@niaid.nih.gov](mailto:pjackson@niaid.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: June 20, 2006.

**Linda Payne,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06–5719 Filed 6–27–06; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Ancillary Studies to Ongoing NIDDK Clinical Research Studies.

*Date:* July 17, 2006.

*Time:* 9 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

*Contact Person:* Carol J. Goter-Robinson, PhD, Scientific Review Administrator, Review Branch, DEA, NIDDK, National Institutes of Health, Room 748, 6707 Democracy Boulevard, Bethesda, MD 20892–5452. (301) 594–7791. [goterrobinsonc@extra.nidk.nih.gov](mailto:goterrobinsonc@extra.nidk.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)